143 related articles for article (PubMed ID: 35754011)
1. "Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism": Reply.
Bistervels IM; Bavalia R; Middeldorp S; Coppens M
J Thromb Haemost; 2022 Jul; 20(7):1748-1749. PubMed ID: 35754011
[No Abstract] [Full Text] [Related]
2. "Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism": Comment.
Lijfering WM
J Thromb Haemost; 2022 Jul; 20(7):1747. PubMed ID: 35754012
[No Abstract] [Full Text] [Related]
3. Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism.
Bistervels IM; Bavalia R; Gebel M; Lensing AWA; Middeldorp S; Prins MH; Coppens M
J Thromb Haemost; 2022 Jun; 20(6):1376-1384. PubMed ID: 35253983
[TBL] [Abstract][Full Text] [Related]
4. Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists.
Di Nisio M; Ageno W; Rutjes AW; Pap AF; Büller HR
Thromb Haemost; 2016 Jan; 115(2):424-32. PubMed ID: 26511068
[TBL] [Abstract][Full Text] [Related]
5. Safety profile of rivaroxaban in first-time users treated for venous thromboembolism in four European countries.
Ruigómez A; Schink T; Voss A; Herings RMC; Smits E; Swart-Polinder K; Balabanova Y; Brobert G; Suzart-Woischnik K; García Rodríguez LA
PLoS One; 2024; 19(3):e0298596. PubMed ID: 38451960
[TBL] [Abstract][Full Text] [Related]
6. Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies.
Khorana AA; Weitz JI
Thromb Haemost; 2018 May; 118(S 01):S23-S33. PubMed ID: 29566417
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
Coleman CI; Bunz TJ; Turpie AGG
Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. An individual patient data meta-analysis.
Bleker SM; Brekelmans MPA; Eerenberg ES; Cohen AT; Middeldorp S; Raskob G; Büller HR
Thromb Haemost; 2017 Oct; 117(10):1944-1951. PubMed ID: 28816341
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of risk of stroke and thrombo-embolism with rivaroxaban versus vitamin K antagonists in ablation and cardioversion of atrial fibrillation.
Nairooz R; Sardar P; Pino M; Aronow WS; Sewani A; Mukherjee D; Paydak H; Maskoun W
Int J Cardiol; 2015; 187():345-53. PubMed ID: 25839640
[TBL] [Abstract][Full Text] [Related]
10. Updated Renal Dosage Recommendations for Rivaroxaban in Patients Experiencing or at Risk of Thromboembolic Disease.
Volkl AA; Moore KT; Haskell L; Barnathan ES
Am J Cardiovasc Drugs; 2023 May; 23(3):247-255. PubMed ID: 37115488
[TBL] [Abstract][Full Text] [Related]
11. Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists.
Eerenberg ES; Middeldorp S; Levi M; Lensing AW; Büller HR
J Thromb Haemost; 2015 Sep; 13(9):1590-6. PubMed ID: 26179293
[TBL] [Abstract][Full Text] [Related]
12. Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism.
Howe Z; Naville-Cook C; Cole D
J Thromb Thrombolysis; 2019 Feb; 47(2):280-286. PubMed ID: 30449001
[TBL] [Abstract][Full Text] [Related]
13. [Not Available].
Själander S; Själander A
Lakartidningen; 2018 Dec; 115():. PubMed ID: 30512136
[No Abstract] [Full Text] [Related]
14. Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism.
Desai A; Desai A; Calixte R; Aparnath M; Hindenburg A; Salzman S; Mathew JP
Lung; 2016 Aug; 194(4):605-11. PubMed ID: 27192990
[TBL] [Abstract][Full Text] [Related]
15. Safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism: a nationwide study.
Sindet-Pedersen C; Staerk L; Pallisgaard JL; Gerds TA; Berger JS; Torp-Pedersen C; Gislason GH; Olesen JB
Eur Heart J Cardiovasc Pharmacother; 2018 Oct; 4(4):220-227. PubMed ID: 29945162
[TBL] [Abstract][Full Text] [Related]
16. Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study.
Stepien K; Nowak K; Zalewski J; Pac A; Undas A
Vascul Pharmacol; 2019 Sep; 120():106567. PubMed ID: 31158568
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: A pilot study.
Signorelli JR; Gandhi AS
J Oncol Pharm Pract; 2019 Mar; 25(2):362-368. PubMed ID: 29157146
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
[TBL] [Abstract][Full Text] [Related]
20. Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer.
Lee JH; Oh YM; Lee SD; Lee JS
J Korean Med Sci; 2019 Jun; 34(21):e160. PubMed ID: 31144482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]